Mirum Pharmaceuticals Announces Health Canada Authorization of Livmarli® for the Treatment of Cholestatic Pruritus in Patients With Progressive Familial Intrahepatic Cholestasis (Pfic)

THOMSON REUTERS
Feb 05

Mirum Pharmaceuticals Announces Health Canada Authorization of Livmarli® for the Treatment of Cholestatic Pruritus in Patients With Progressive Familial Intrahepatic Cholestasis (Pfic)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10